Olivier Vercruysse

Most-cited papers

1. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

   J. Dumurgier, S. Schraen, A. Gabelle, Olivier Vercruysse +11 more

   2015Alzheimer's Research & Therapy139 citations Open access

   Semantic Scholar

   Save

2. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

   J. Dumurgier, Olivier Vercruysse, C. Paquet, S. Bombois +9 more

   2013Alzheimer's & Dementia74 citations

   Semantic Scholar

   Save

3. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis

   S. Lehmann, S. Schraen, I. Quadrio, C. Paquet +18 more

   2014Alzheimer's & Dementia69 citations

   Semantic Scholar

   Save

4. Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study

   A. Gabelle, J. Dumurgier, Olivier Vercruysse, C. Paquet +9 more

   2013Journal of Alzheimer's Disease55 citations

   Semantic Scholar

   Save

5. A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

   S. Lehmann, J. Dumurgier, S. Schraen, D. Wallon +21 more

   2014Alzheimer's Research & Therapy51 citations Open access

   Semantic Scholar

   Save

6. Impact of Overwhelming Joy on Consumer Demand

   J. Falter, C. Pérignon, Olivier Vercruysse

   200833 citations

   Semantic Scholar

   Save

7. Assessment of Mendelian and risk factor genes in Alzheimer disease: a prospective nationwide clinical utility study and recommendations for genetic screening.

   G. Nicolas, A. Zaréa, Morgane Lacour, O. Quenez +114 more

   2024Genetics in Medicine21 citations Open access

   Semantic Scholar

   Save

8. Exacerbated CSF abnormalities in younger patients with Alzheimer's disease.

   J. Dumurgier, A. Gabelle, Olivier Vercruysse, S. Bombois +9 more

   2013Neurobiology of Disease17 citations Open access

   Semantic Scholar

   Save

9. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers.

   Olivier Vercruysse, C. Paquet, A. Gabelle, X. Delbeuck +20 more

   2018Current Alzheimer Research7 citations

   Semantic Scholar

   Save

10. A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

    S. Lehmann, J. Dumurgier, S. Schraen, D. Wallon +21 more

    2014Alzheimer's Research & Therapy2 citations Open access

    Semantic Scholar

    Save

11. O1–09–02: Beyond interest and limits of CSF biomarkers in clinical practice: The PLM study

    A. Gabelle, J. Dumurgier, Olivier Vercruysse, C. Paquet +9 more

    20131 citations

    Semantic Scholar

    Save

12. Estimating the prevalence of amyloid positivity among older adults without dementia in the general population

    L. Le Scouarnec, V. Bouteloup, T. Daly, V. Planche +404 more

    2026npj Dementia0 citations Open access

    Semantic Scholar

    Save

13. P1‐128: C9ORF72 EXPANSION DOES NOT HAVE EFFECTS ON CSF TDP‐43 LEVELS IN FTLD PATIENTS

    A. Gabelle, J. Dumurgier, S. Bombois, D. Wallon +17 more

    20140 citations

    Semantic Scholar

    Save

14. P2‐114: BRAIN AND CEREBROSPINAL FLUID C‐JUN N TERMINAL KINASE 3 LEVELS IN ALZHEIMER'S DISEASE: LINKS TO COGNITIVE DECLINE

    J. Hugon, J. Dumurgier, Susanna Schraen, A. Gabelle +9 more

    20140 citations Open access

    Semantic Scholar

    Save

15. P1–153: Increasing age and CSF biomarker levels in Alzheimer's disease: The PLM study

    J. Dumurgier, J. Hugon, A. Gabelle, Olivier Vercruysse +8 more

    20130 citations

    Semantic Scholar

    Save

16. P1‐110: Comparison of diagnostic power of cerebrospinal fluid Aß and Tau variables for Alzheimer's disease diagnosis: proposition of a simple decision tree

    S. Schraen-Maschke, Olivier Vercruysse, Nicolas Sergeant, L. Buée +5 more

    20110 citations

    Semantic Scholar

    Save